Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Winding back Wnt signalling: Potential therapeutic targets for treating gastric cancers

    Access Status
    Open access via publisher
    Authors
    Flanagan, D.
    Vincan, Elizabeth
    Phesse, T.
    Date
    2017
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Flanagan, D. and Vincan, E. and Phesse, T. 2017. Winding back Wnt signalling: Potential therapeutic targets for treating gastric cancers. British Journal of Pharmacology.
    Source Title
    British Journal of Pharmacology
    DOI
    10.1111/bph.13890
    ISSN
    0007-1188
    School
    School of Biomedical Sciences
    URI
    http://hdl.handle.net/20.500.11937/55917
    Collection
    • Curtin Research Publications
    Abstract

    © 2017 The British Pharmacological Society. Gastric cancer persists as a frequent and deadly disease that claims over 700000 lives annually. Gastric cancer is a multifactorial disease that is genetically, cytologically and architecturally more heterogeneous than other gastrointestinal cancers, making it therapeutically challenging. As such, and largely attributed to late-stage diagnosis, gastric cancer patients show only partial response to standard chemo and targeted molecular therapies, highlighting an urgent need to develop new targeted therapies for this disease. Wnt signalling has a well-documented history in the genesis of many cancers and is, therefore, an attractive therapeutic target. As such, drug discovery has focused on developing inhibitors that target multiple nodes of the Wnt signalling cascade, some of which have progressed to clinical trials. The collective efforts of patient genomic profiling has uncovered genetic lesions to multiple components of the Wnt pathway in gastric cancer patients, which strongly suggest that Wnt-targeted therapies could offer therapeutic benefits for gastric cancer patients. These data have been supported by studies in mouse models of gastric cancer, which identify Wnt signalling as a driver of gastric tumourigenesis. Here, we review the current literature regarding Wnt signalling in gastric cancer and highlight the suitability of each class of Wnt inhibitor as a potential treatment for gastric cancer patients, in relation to the type of Wnt deregulation observed.

    Related items

    Showing items related by title, author, creator and subject.

    • Stomach-specific activation of oncogenic KRAS and STAT3-dependent inflammation cooperatively promote gastric tumorigenesis in a preclinical model
      Thiem, S.; Eissmann, M.; Elzer, J.; Jonas, A.; Putoczki, T.; Poh, A.; Nguyen, P.; Preaudet, A.; Flanagan, D.; Vincan, Elizabeth; Waring, P.; Buchert, M.; Jarnicki, A.; Ernst, M. (2016)
      About 5% to 10% of human gastric tumors harbor oncogenic mutations in the KRAS pathway, but their presence alone is often insufficient for inducing gastric tumorigenesis, suggesting a requirement for additional mutagenic ...
    • Loss of the Wnt receptor frizzled 7 in the mouse gastric epithelium is deleterious and triggers rapid repopulation in vivo
      Flanagan, D.; Barker, N.; Nowell, C.; Clevers, H.; Ernst, M.; Phesse, T.; Vincan, Elizabeth (2017)
      The gastric epithelium consists of tubular glandular units, each containing several differentiated cell types, and populations of stem cells, which enable the stomach to secrete the acid, mucus and various digestive enzymes ...
    • Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
      Singh, S.; Yap, W.; Arfuso, Frank; Kar, S.; Wang, C.; Cai, W.; Dharmarajan, Arunasalam; Sethi, Gautam; Kumar, Alan Prem (2015)
      Frequent activation of phosphatidylinositol-3 kinases (PI3K)/Akt/mTOR signaling pathway in gastric cancer (GC) is gaining immense popularity with identification of mutations and/or amplifications of PIK3CA gene or loss ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.